Feasibility evaluation of middle-phase 18F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment
Open Access
- 1 August 2023
- journal article
- research article
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 13 (8) , 4806-4815
Abstract
Background: 18F-florbetaben (FBB) positron emission tomography (PET) scan has been widely used in research and routine clinical practice. Most studies used late-phase (scanning from 90 to 110 min after injection) FBB scans to generate beta-amyloid accumulation data. The feasibility of middle-phase scan is seldom discussed. Using the middle-phase data can shorten the patients’ waiting between the injection and scan, and hospital can acquire more flexible schedule of routine scan. Methods: Paired middle-phase (60–80 min) FBB scans and standard (90–110 min) FBB scans were obtained from 27 subjects (12 neurodegenerative dementia, 8 mild cognitive impairment, 3 normal control, and 4 patients not suffering from neurodegenerative dementia). Standardized uptake value ratios (SUVRs) were calculated and converted to centiloid (CL) scale to investigate the impact on image quantification. CL pipeline validation were performed to build an equation converting the middle-phase data into equivalent standard scans. Cohen’s kappa of binary interpretation and brain amyloid plaque load (BAPL) score were also used to evaluate the intrareader agreement of the FBB image from the two protocols. Results: The middle-phase FBB SUVR showed an excellent correlation, which provided a linear regression equation of SUVRFBB60–80 = 0.88 × SUVRFBB90–110 + 0.07, with R2=0.98. The slope of the equation indicated that there was bias between the middle and standard acquisition. This can be converted into the CL scale using CL = 174.68 × SUVR − 166.39. Cohen’s kappa of binary interpretation and BAPL score were 1.0 (PConclusions: Our findings indicate that the middle-phase FBB protocol is feasible in clinical applications for scans that are at either end of beta-amyloid spectrum, which provides comparable semiquantitative results to standard scan. Patient’s waiting time between the injection and scan can be shortened.Keywords
This publication has 40 references indexed in Scilit:
- PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human BrainsJournal of Nuclear Medicine, 2013
- Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification MethodsJournal of Nuclear Medicine, 2012
- [18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studiesActa Neuropathologica, 2012
- Amyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other DementiasJournal of Nuclear Medicine, 2011
- Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controlsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Quantitative Approaches to Amyloid Imaging2010
- In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)Journal of Nuclear Medicine, 2010
- Amyloid PET Ligands for DementiaPET Clinics, 2010
- Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004